SNY

Over the past six months, Sanofi's stock experienced some notable events and performance. As of May 8, 2026, SNY was down 8.12% over the past 30 days and down 16.92% over the past 12 months. In April 2026, Sanofi announced strong financial results for Q1 2026, reporting double-digit sales and business EPS growth. Despite positive earnings, Sanofi shares dropped to a new low of €72.78 in early May 2026. In March 2026, Sanofi launched an innovation and operation center in Chengdu, China, expanding its R&D footprint. Sanofi has been advancing early-stage RSV and H5 Flu vaccine trials, bolstering its respiratory pipeline. The company also received several regulatory approvals in immunology and positive pipeline readouts. There were reports of disappointing readouts starting in 2025, adding pressure to develop or acquire assets to replace Dupixent before its loss of exclusivity. Sanofi announced a leadership evolution in its Specialty Care Business Unit, and its shares fell after a CEO change.